Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of 4D-110 in Choroideremia
NCT04483440Phase 1Active, not recruiting
- Sponsor
- 4D Molecular Therapeutics
- Start
- Jun 2020
- Primary completion
- May 2027
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 1, open-label trial of 4D-110 in choroideremia (3 arms), sponsored by 4D Molecular Therapeutics. Primary endpoint: Frequency and severity of ocular and systemic adverse events at 24 months. Started Jun 2020; status: active, not recruiting.
02
Drugs
4D-110
03
Conditions
choroideremia
Beyond the preview
Go deeper on NCT04483440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04483440.